


ALL ACUTE LYMPHOCYTIC LEUKEMIA WORKING GROUP MEETING 3



25 SATURDAY MAY 2024

05:30 PM – 08:00 PM (UAE TIME)

04:30 PM – 07:00 PM (KWT TIME)

VIRTUAL GULF ADVISORY BOARD

JOIN MEETING

MODERATOR



Dr. Murtadha Al Khabori

Consultant Hematologist at Sultan Qaboos University Hospital

INVITED INTERNATIONAL ADVISOR



Dr. Mark Litzow

Professor of Medicine in the Division of Hematology at Mayo Clinic. He Was the Director of the BMT Program at Mayo from 1992 to 2008 and Continues to Remain Active in the BMT Program.

He Was Appointed as Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) in September 2013 After Having Served as Co-Chair of the Committee from 2001 to 2011.

ALL ADVISORS\*




Dr. Mahmoud Marashi

Consultant Hematologist at Mediclinic City Hospital / Dubai Hospital



Dr. Faraz Khan

Consultant Hematologist and Medical Oncologist, American Hospital, Dubai, UAE



Dr. Ahmed Al Huraiji

Consultant Hematologist at Kuwait Cancer Control Center



Dr. Hasan Al Yaseen

Consultant Hematologist at Dubai Hospital



Dr. Arif Alam

Consultant Hematologist at Tawam Hospital



Dr. Ruba Taha

Consultant Hematologist at National Center for Cancer Care & Research



Dr. Murtadha Al Khabori

Consultant Hematologist at Sultan Qaboos University Hospital

AGENDA

TIME	SESSION	SPEAKER	MODERATOR
	Introduction & Welcome	Amgen Team	
05:30 – 05:40 pm	Current Treatment Paradigms in Gulf in Ph- B-ALL Pre ad board survey Qs related to E1910	Dr. Murtadha Al Khabori	
05:40 – 06:00 pm	Deep Dive into E1910	Dr. Mark Litzow	
06:00 – 06:30 pm	Discussion Points	ALL Advisors + Dr. Mark Litzow	
06:30 – 08:00 pm	Similarities and Difference in Chemotherapy Backbone Workshop - What is your perception of E1910 chemotherapy backbone compared to HCVAD+INO+Blin? Dr. Hasan Al Yaseen experience from Dubai Hospital (10 mins)  - E2993/UKALLXII protocol discussion  E1910 Data Discussion - What impact will the concept of the E1910 study have on your treatment practice? - Can the data be extrapolated to other chemo backbones?  - Would you consider Blin as consolidation in 1L regardless of MRD status? If yes, how many cycles of Blin would you use?  - Which specific subgroups do you think would benefit most/least from this treatment approach and why?  • Can the E1910 data be extrapolated to patients younger than age 30 in clinical practice? Why or why not? • Would you consider re-treatment with Blin at MRD+? If not, what would be your preferred options at MRD+?	ALL Advisors + Dr. Mark Litzow	
08:00 pm	Closing Remarks	Amgen Team	

Dr. Murtadha Al Khabori